EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 258 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate... January 11, 2022 E-cigarettes: what we know and what we don’t April 26, 2021 ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland November 29, 2023 If You Let It, Nursing Will Change Your Life May 24, 2021 Load more HOT NEWS FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... Woman Helps Students With Special Needs Achieve Success After Graduation Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and...
